Brokerages Set Acelyrin, Inc. (NASDAQ:SLRN) PT at $11.17

Acelyrin, Inc. (NASDAQ:SLRN) has been assigned an average recommendation of “Moderate Buy” from the six brokerages that are covering the company, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $11.17.

SLRN has been the subject of several analyst reports. Piper Sandler dropped their price objective on shares of Acelyrin from $68.00 to $20.00 and set an “overweight” rating for the company in a research note on Wednesday, August 14th. Morgan Stanley decreased their target price on shares of Acelyrin from $13.00 to $6.00 and set an “equal weight” rating on the stock in a report on Monday, August 19th. HC Wainwright lowered shares of Acelyrin from a “buy” rating to a “neutral” rating and decreased their target price for the company from $18.00 to $6.00 in a report on Wednesday, August 14th. Finally, Wells Fargo & Company raised their target price on shares of Acelyrin from $13.00 to $15.00 and gave the company an “overweight” rating in a report on Wednesday, October 16th.

Institutional Investors Weigh In On Acelyrin

Several hedge funds and other institutional investors have recently made changes to their positions in SLRN. Russell Investments Group Ltd. bought a new stake in shares of Acelyrin during the 1st quarter valued at approximately $183,000. ProShare Advisors LLC boosted its position in Acelyrin by 69.9% during the 1st quarter. ProShare Advisors LLC now owns 19,871 shares of the company’s stock worth $134,000 after buying an additional 8,176 shares during the period. Blair William & Co. IL acquired a new stake in Acelyrin during the 1st quarter worth approximately $936,000. Vanguard Group Inc. boosted its position in Acelyrin by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 6,237,543 shares of the company’s stock worth $42,103,000 after buying an additional 81,633 shares during the period. Finally, Ameritas Investment Partners Inc. boosted its position in Acelyrin by 118.0% during the 1st quarter. Ameritas Investment Partners Inc. now owns 7,243 shares of the company’s stock worth $49,000 after buying an additional 3,921 shares during the period. 87.31% of the stock is owned by institutional investors.

Acelyrin Stock Down 7.8 %

Shares of Acelyrin stock opened at $5.90 on Monday. Acelyrin has a twelve month low of $3.36 and a twelve month high of $10.50. The company has a 50-day simple moving average of $5.16 and a two-hundred day simple moving average of $4.94. The stock has a market capitalization of $584.26 million, a price-to-earnings ratio of -2.48 and a beta of 2.33.

Acelyrin (NASDAQ:SLRN) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.78) by ($0.08). During the same period last year, the business posted ($0.56) EPS. On average, sell-side analysts anticipate that Acelyrin will post -3.08 earnings per share for the current fiscal year.

Acelyrin Company Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.